6550--Notice of Intent to Sole-Source T-SPOT.TB® Reagents and Kits
Veterans Affairs · 242-NETWORK CONTRACT OFFICE 02 (36C242)
Capture briefs (a one-page, shareable copy of this page) are part of Pro. The CSV here holds the notice, its timeline and past awards.
Where this opportunity stands
Every notice posted under solicitation 36C24227Q0036 in this department, oldest first.
- Oct 2, 2026 · this noticeSpecial Notice
Next steps for this stage
Standard steps for the notice type; not advice about this buyer.
- Answer the notice: this is when the requirement can still be shaped.
- Contact the contracting officer named on the notice.
- Check who won similar work; they are the likely bidders.
What the notice says
This notice is being published in accordance with Revolutionary FAR Overhaul Federal Acquisition Regulation (RFO FAR) Subpart 5.101 requiring dissemination of information for proposed contract actions. The Department of Veterans Affairs, Network Contracting Office (NCO) 2, hereby provides notice of its intent to award a sole source, firm fixed price contract to Euroimmun US Incorporated, the sole authorized U.S. distributor of T SPOT.TB® reagents and associated kits manufactured by Oxford Immunotec. These reagents are required for tuberculosis testing at VA Western New York Healthcare System (… (show all)
VAWNYHS) Buffalo VA Medical Center (VAMC). This determination is made in accordance with RFO FAR 12.201-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The T SPOT.TB® assay is a patented IGRA platform, and its reagents including the antigen panels, controls, and AIM V media are proprietary and FDA cleared only for use with the OEM platform. Oxford Immunotec holds the exclusive patent rights, and Euroimmun US Incorporated is the only supplier legally authorized to provide these FDA approved reagents for federal healthcare facilities. No other vendor can supply reagents that meet FDA, CLIA, CAP, and Joint Commission requirements. This notice is not a request for competitive quotes. However, interested parties may identify their interest and capability to respond to this requirement by submitting a: Capability Statement (1 page maximum) Company Name UEI Number Socioeconomic Status Proof of authorization to provide the OEM reagents Responses must be received no later than 4:00 PM EST on October 16, 2026 to Myra.Green2@va.gov A determination not to compete this proposed action is solely within the discretion of the Government. Information received will only be considered for determining whether to conduct a competitive procurement in the future. Prospective contractors must be registered in SAM.gov to be eligible for award.
Who won similar work
5 award notices on SAM.gov in the last 24 months. Matched by: Same office (242-NETWORK CONTRACT OFFICE 02 (36C242)), same product/service code (PSC) 6550.
Single-winner award sizes (5): middle half $388K to $1.1M, median $920K; range $248K to $1.1M.
| Winner | Awards | Value | Last |
|---|---|---|---|
| NOVA BIOMEDICAL CORP | 1 | $1.1M | Sep 28, 2026 |
| POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC | 1 | $1.1M | Oct 9, 2025 |
| ABBOTT MOLECULAR INC. · $ABT · $45.1B | 1 | $920K | Oct 6, 2026 |
| WERFEN USA LLC | 1 | $388K | Oct 1, 2026 |
| 10X GENOMICS, INC. · $TXG · $616.9M | 1 | $248K | Sep 25, 2025 |
Value counts single-winner awards. "Shared" awards are multiple-award contracts that list every winner with the same total ceiling; that ceiling is not one company's win, so it is not added in. Revenue next to a ticker is the company's last annual revenue from its 10-K.
- $ABT reported $45.1B revenue (12 months to Mar 31, 2026). The median single-winner award in these 5 past awards, $920K, is under 0.1% of that. SEC filing
- $TXG reported $616.9M revenue (12 months to Jun 30, 2026). The median single-winner award in these 5 past awards, $920K, is 0.1% of that. SEC filing
One award's total value against one year of revenue; many awards are paid over several years.
- Oct 6, 2026ABBOTT MOLECULAR INC.$920K6550--LAB - ABBOTT ALINITY-M PCR MOLECULAR REAGENTS & SUPPLIESMateriality: <0.01% of $ABT revenue (Low) SEC
- Oct 1, 2026WERFEN USA LLC$388K6550--Werfen Immunocor Blood Bank Reagents and Supplies Northport and East OrangeNo listed company matched (Materiality N/A)
- Sep 28, 2026NOVA BIOMEDICAL CORP$1.1M6550--Glucose Point of Care (POC) TestingNo listed company matched (Materiality N/A)
- Oct 9, 2025POLYMEDCO CANCER DIAGNOSTIC PRODUCTS LLC$1.1MAward Notice - VISN 2 Fecal Immunochemical Testing (FIT)No listed company matched (Materiality N/A)
- Sep 25, 202510X GENOMICS, INC.$248K6550--SUPPLY - GENE EXPRESSION KITSMateriality: 0.04% of $TXG revenue (Low) SEC
Materiality: one award's value as a share of the winner's revenue over the latest 12 months in its SEC filings (or its last fiscal year, as noted when you point at it). Low under 1%, Medium 1 to 5%, High 5% or more. Many awards are paid over several years, so this overstates a single year's share.
Competitive landscape
For the 5 most frequent past winners above. Lobbying is matched by the company's exact name or exact ticker; agencies are as named on the filings.
- 1 of these past winners lobbied Veterans Affairs, Dept of (VA) since 2024 (5 filings)
- 0 of their lobbyists list a past Veterans Affairs, Dept of (VA) job
- $48K from their corporate PACs since 2024 to members of House Committee on Appropriations, House Committee on Veterans' Affairs, Senate Committee on Appropriations, Senate Committee on Veterans' Affairs
- 0 foreign-agent (FARA) registrations
Policy around it
Bills the past winners named while lobbying this agency's issues, rules from the department, and executive orders that name the agency, last 12 months.
- 5 bills named on the past winners' lobbying filings
- 25 rules from the department in the last 12 months
- 0 executive orders naming the agency in the last 12 months
Market
For past winners matched exactly to a listed company. Insider trades are open-market buys and sells (Form 4) in the last 90 days, shown as facts; our own study found insiders do not reliably buy ahead of awards. A sale marked 10b5-1 was made under a trading plan set up in advance.
- 2 of the past winners are listed companies
- 0 insider buys and 5 insider sells at them in the last 90 days
Sources: SAM.gov notices and award notices; Senate LDA lobbying filings; FEC filings; FARA; Federal Register; congress.gov; SEC Form 4. Every row above links to its record.
Companies are matched to tickers by exact name only. A company we could not match shows no market rows; that is a miss, not a finding.